Article
Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy.
Nucleic acids research - 1 Jan 2006
Albertini Veronica, Jain Aklank, Vignati Sara, Napoli Sara, Rinaldi Andrea, Kwee Ivo, Nur-e-Alam Mohammad, Bergant Julia, Bertoni Francesco, Carbone Giuseppina M, Rohr Jürgen, Catapano Carlo V
Abstract excerpt
The aureolic acid antibiotic mithramycin (MTM) binds selectively to GC-rich DNA sequences and blocks preferentially binding of proteins, like Sp1 transcription factors, to GC-rich elements in gene promoters. Genetic approaches can be applied to alter the MTM biosynthetic pathway in the producing microorganism and obtain new products with improved pharmacological properties. Here, we report on a new analog, MTM...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.